FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	2225 02

Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  RATOFF STEVEN B					<u>E</u> /	2. Issuer Name <b>and</b> Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [ EGRX ]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				vner
(Last)	(F	irst)	(Middle)													Officer below)	(give title		Other (s below)	specify
C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315						3. Date of Earliest Transaction (Month/Day/Year) 03/04/2019														
(Street) WOODCLIFF LAKE NJ 07677				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
		Tab	le I - Nor	n-Deriv	ative	Se	curit	ies Ad	qui	red, D	isp	osed o	f, or Be	enef	iciall	y Owned	ŀ			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution I			·,   7	3. Transaction Code (Instr. 8)  4. Securities Acqui Disposed Of (D) (In					Beneficially Owned Following		Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
										Code V	,	Amount	(A) c (D)	r P	rice	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 03/04/						/2019				M		2,340 A			\$4.04	18	18,004		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		ransaction Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	/e es ally ng d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	e rcisable	Ex Da	piration te	Title	or	ount nber ıres					
Stock Option (right to buy)	\$4.04	03/04/2019			M			2,340		(1)	03.	/06/2019	Common Stock	2,3	340	\$0.00	0		D	

### **Explanation of Responses:**

1. These shares are fully vested and immediately exercisable.

## Remarks:

/s/ Scott Tarriff, Attorney-in-

03/06/2019

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.